MARKET OUTLOOK The availability of multiple targeted therapies with diverse mechanisms of action, including biologics / biosimilars and oral agents, together with conventional treatments, makes…
Pustular psoriasis is a rare subtype of psoriasis, typically seen as pustules that erupt generally across the body (generalized pustular psoriasis [GPP]) or are localized, typically on the hands…
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the development and progressive enlargement of fluid-filled cysts in the kidneys. Particularly in the…
DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key type 1 diabetes patient populations covering 171 countries and more than…
The biosimilar/noninnovator sector of the endocrinology market is evolving. Eli Lilly/Boehringer Ingelheim’s Abasaglar/Basaglar was the first biosimilar/noninnovator insulin glargine to launch in…
Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by varying degrees of hair loss. The host immune system targets anagen hair follicles. The primary treatment goal is to…
TNF-α inhibitors are well entrenched in the U.S. ulcerative colitis (UC) and Crohn’s disease (CD) markets. Newer biologics that offer alternative treatment options (i.e., Takeda’s Entyvio and…
MARKET OUTLOOK The dynamics within the LABA/ICS FDC, LAMA, and biological drug classes will continue to shape the U.S. asthma market. The dominance of branded LABA/ICS FDCs (e.g., GlaxoSmithKline…
The U.S. glaucoma market has seen notable advances in the treatment of OAG following the launches of numerous innovative drugs over the past two years, including Bausch + Lomb’s Vyzulta and…
MARKET OUTLOOK The European atopic dermatitis (AD) market has entered a new era. In 2017, IL-4/13 inhibitor Dupixent (Sanofi/Regeneron) became the first targeted biologic to be approved for…
Given the seemingly constant failure of emerging disease-modifying therapies (DMTs) in Alzheimer's disease (AD) that target the amyloid cascade, industry has gradually expanded its focus to…
The development of biosimilar versions of Lucentis and Eylea is of high interest in the ophthalmology market given the high cost of these agents, the large patient population suffering from retinal…
The development of biosimilar versions of Lucentis and Eylea is of high interest in the ophthalmology market given the high cost of these agents, the large patient population suffering from retinal…
Instructions for uploading your PowerPoint presentation and survey: The PPT attachment needs to be the first node under the report (i.e., it should appear before your survey).Name the PPT in the…
The most highly anticipated analgesic drugs in late-phase development belong to the anti-nerve growth factor (NGF) class: Pfizer / Eli Lilly’s tanezumab and Regeneron / Teva / Mitsubishi Tanabe…
